Finvest
ACAD Biotechnology · CNS drugs · Rare disease · Commercial biotech · Thesis updated July 1, 2026

DAYBUE helps, but ACP-204 still decides upside

01 Running thesis

Two drugs, one big readout

ACADIA is no longer a pure research story. It sells two FDA-approved medicines and uses that cash to fund more CNS drug work. Q1 2026 showed why the setup is interesting: DAYBUE had $101.2 million of net sales and grew 20% year over year, helped by strong early demand for DAYBUE STIX.

NUPLAZID is the steadier part of the story. It had $166.9 million of Q1 2026 net sales. Growth was only 6% on an adjusted basis because some patients refilled later than usual in January and February, but management said that issue had normalized.

The Europe question for DAYBUE improved after the CHMP gave Daybu a positive opinion in June 2026. That lowered a major overhang, but final European Commission approval is still the next legal step. It also does not solve the bigger question of how much global demand can grow after the first waves of use.

The main swing factor is ACP-204, also called remlifanserin, in Alzheimer's disease psychosis. Top-line Phase 2 results are expected from August to October 2026. A strong result could open a large market. A weak result would leave ACADIA much more dependent on NUPLAZID and DAYBUE.

Jun 2026Daybu received a positive CHMP recommendation in Europe after an earlier negative review process. This improves the DAYBUE global story, while final European Commission approval remains pending.
May 2026The Q1 2026 10-Q confirmed product sales already reported by management. NUPLAZID net sales were $166.9 million and DAYBUE net sales were $101.2 million.
May 2026Q1 showed strong DAYBUE momentum, with sales up 20% year over year and STIX uptake faster than expected. NUPLAZID was softer because of a temporary refill lag that management said had normalized.
Feb 2026The 2025 10-K added pressure points around NUPLAZID, including an $11.8 million unfavorable gross-to-net adjustment tied to Medicare rebates and a future Medicare pricing risk.
Feb 2026Full-year 2025 revenue passed $1 billion and 2026 guidance called for more growth, but DAYBUE's negative CHMP trend vote created a new Europe overhang.
Nov 2025ACP-101 failed in Prader-Willi syndrome and was discontinued, removing a major pipeline asset. Strong NUPLAZID and DAYBUE sales partly offset the damage.
02 Business model

Sales fund the science

ACADIA makes money by selling prescription drugs. NUPLAZID treats hallucinations and delusions linked to Parkinson's disease psychosis. DAYBUE treats Rett syndrome, a rare brain and development disorder.

This model is healthier than many biotech models because the company is commercial stage, cash-flow positive, and has no debt in the internal view. That means its existing products can help pay for research instead of relying only on new stock sales or borrowing.

The weak point is concentration. All product revenue comes from two medicines. If DAYBUE use slows, NUPLAZID loses exclusivity earlier than hoped, or ACP-204 fails, the long-term growth story gets thinner fast.

Valuation also matters. The business is better funded than many biotech peers, but Finn's valuation score is modest, so investors are already paying for part of the good news.

03 Product portfolio

What ACADIA sells and studies

Cash cow

NUPLAZID

NUPLAZID is approved in the U.S. for hallucinations and delusions tied to Parkinson's disease psychosis. It is the mature profit engine, but refill timing, rebates, exclusivity, and future Medicare pricing all matter.

Growth engine

DAYBUE

DAYBUE is the first FDA-approved treatment for Rett syndrome. Q1 2026 net sales were $101.2 million, and the new STIX powder form appears to be helping adoption.

Option

Daybu in Europe

Daybu, the European name for trofinetide, received a positive CHMP opinion in June 2026 after an earlier negative process. Final European Commission approval is still needed before broad EU commercialization.

Option

ACP-204

ACP-204 is a next-generation 5HT2A compound being tested in Alzheimer's disease psychosis. The August to October 2026 Phase 2 readout is the biggest near-term pipeline event.

Option

ACP-711

ACP-711 is a potential first-in-class GABA-Alpha-3 positive allosteric modulator for essential tremor. A Phase 2 study is expected to begin in Q4 2026 or Q1 2027.

Option

ACP-271

ACP-271 is a GPR88 agonist aimed at tardive dyskinesia and Huntington's disease. A Phase 1 study was planned for Q1 2026 in the internal pipeline view.

Steady

ACP-101

ACP-101 was once a Phase 3 candidate for Prader-Willi syndrome. Development was stopped in September 2025, so it is no longer a growth driver.

04 Business segments

Revenue is all product sales

NUPLAZID62%modest
DAYBUE38%growing fast

ACADIA reports as one operating segment, but Q1 2026 product sales were split between NUPLAZID and DAYBUE. The mix below uses Q1 2026 net product sales of $166.9 million for NUPLAZID and $101.2 million for DAYBUE.

05 Risk factors

What could break the thesis

ACP-204 misses in Alzheimer's disease psychosis

High impact · Medium odds

The pipeline is now heavily tied to ACP-204 after ACP-101 was discontinued. A weak Phase 2 result would remove the largest near-term value creation chance and make the company look more like a two-product commercial biotech.

We watchTop-line ACP-204 Phase 2 data expected from August to October 2026, especially the SAPS-HD primary endpoint.

DAYBUE STIX uptake fades

High impact · Medium odds

Q1 2026 strength came partly from faster than expected STIX uptake. The key question is whether that continues and whether it brings back patients who stopped the liquid form. If persistency does not improve, early demand could prove front-loaded.

We watchDAYBUE quarterly net sales, new prescriptions, restarts, and comments on persistency after STIX launch.

Europe approval still stalls

Medium impact · Low odds

The June 2026 positive CHMP opinion lowered the risk for Daybu in Europe. Still, the European Commission must issue final legal approval before the product can move into a real EU launch. Pricing and reimbursement by country can also slow revenue even after approval.

We watchEuropean Commission decision on Daybu and later country-by-country reimbursement updates.

NUPLAZID growth re-slows

Medium impact · Medium odds

NUPLAZID is a mature franchise. Q1 2026 had a patient refill lag that management called temporary, but it showed how quarterly sales can wobble. Higher rebates also hurt historical net revenue in 2025.

We watchNUPLAZID quarterly net sales versus 2026 guidance, refill trends, gross-to-net adjustments, and sales force productivity.

Exclusivity and pricing pressure

Medium impact · Medium odds

ACADIA believes it met requirements for a six-month pediatric exclusivity extension for NUPLAZID, but FDA approval is not guaranteed. NUPLAZID could also face Medicare price negotiation as early as 2029, though the company expects possible small manufacturer exemptions to limit early impact.

We watchFDA decision on pediatric exclusivity and any updates on Medicare negotiation timing or exemption status.
06 Quick answers

In one breath

What does ACADIA Pharmaceuticals do?

ACADIA develops and sells drugs for central nervous system disorders. Its main products are NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome.

Why does DAYBUE STIX matter?

DAYBUE STIX is a powder form of DAYBUE. Management said early uptake was faster than expected, which could help new patients start treatment and some former patients restart.

What is the biggest ACADIA catalyst in 2026?

The biggest clinical catalyst is the ACP-204 Phase 2 readout in Alzheimer's disease psychosis, expected from August to October 2026. A positive result could change the long-term growth outlook.

Is ACADIA profitable?

The internal company view describes ACADIA as cash-flow positive with no debt. That gives it more flexibility than many biotechs, but the business still depends on two products and clinical trial success.